Atypical Manifestations of Dengue Fever: A Narrative Review
Keywords:
AKI, ARDS, atypical manifestations, Dengue fever, MyocarditisAbstract
Dengue fever (DF) is an arboviral infection caused by one of four serotypes of the dengue virus. The worldwide burden of DF is high with a low fatality rate. It is endemic in tropical and sub-tropical regions. It is transmitted by mosquito bites. After a certain incubation period, it produces typical symptoms of fever, body ache, and headache with low blood pressure and thrombocytopenia. However, there are several atypical manifestations of DF such as acalculous cholecystitis, hepatitis, fulminant hepatic failure, acute pancreatitis, febrile diarrhea, encephalopathy, seizure, meningitis, encephalitis, acute motor weakness, myocarditis, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and myositis, which are often overlooked leading to delayed diagnosis and high morbidity and mortality. This narrative review has compiled different atypical manifestations of DF. This article would be beneficial for clinicians to diagnose DF with atypical presentations early and save many lives by timely interventions.
References
World Health Organization. Ten threats to global health in 2019. [Online]. Available from: https://www.who.int/news-room/feature-stories/ten-threats-to-global-health-in-2019. [Cited on 21 November 2019].
World Health Organization. Dengue and severe dengue. [Online]. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. [Cited on 3 November 2019].
Dejnirattisai W, Duangchinda T, Lin CL, Vasanawathana S, Jones M, et al. A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J Immunol.2008; 181(9):pp.5865-74. https://pubmed.ncbi.nlm.nih.gov/18941175/
Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis.2006; 19(5):pp.429-36. https://pubmed.ncbi.nlm.nih.gov/16940865/
Restrepo BN, Ramirez RE, Arboleda M, Alvarez G, Ospina M, et al. Serum levels of cytokines in two ethnic groups with dengue virus infection. Am J Trop Med Hyg.2008; 79(5):pp.673-7. https://www.unboundmedicine.com/medline/citation/18981502/
Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science.2010; 328(5979):pp.745-8. https://pubmed.ncbi.nlm.nih.gov/20448183/
Schmidt AC. Response to dengue fever--the good, the bad, and the ugly?. N Engl J Med.2010; 363(5):pp.484-7. https://pubmed.ncbi.nlm.nih.gov/20818870/
Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol.2008; 62:pp.71-92. https://pubmed.ncbi.nlm.nih.gov/18429680/
Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health.2007; 12(9):pp.1087–95. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-3156.2007.01891.x
Nimmagadda SS, Mahabala C, Boloor A, Raghuram PM, Nayak U A. Atypical Manifestations of Dengue Fever (DF) - Where Do We Stand Today? J Clin Diagn Res.2014; 8(1):pp.71-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939591/
Souza LJ De, Alves JG, Bastos DA, Wallace E. Aminotransferase changes and acute hepatitis in patients with dengue fever: Analysis of 1,585 cases. Braz J Infect Dis.2004; 8:pp.156–63. https://pubmed.ncbi.nlm.nih.gov/15361994/
Koh FH, Misli H, Chong VH. Acute acalculous cholecystitis secondary to dengue fever. Brunei Int Med J.2011; 7(1):pp.45–49.
Wu KL, Changchien CS, Kuo CM, Chuah SK, Lu SN. Dengue fever with acute acalculous cholecystitis. Am J Trop Med Hyg.2003; 68(6):pp.657–60. https://pubmed.ncbi.nlm.nih.gov/12887023/
Bhatty S, Shaikh NA, Fatima M, Sumbhuani AK. Original Article Acute acalculous cholecystitis in dengue fever. J Pak Med Assoc.2009; 59(8):pp.519–21. https://pubmed.ncbi.nlm.nih.gov/19757695/
Shapiro MJ, Luchtefeld WB, Kurzweil S, Kaminski DL, Durham RM, et al. Acute acalculous cholecystitis in the critically ill. Am Surg.1994; 60:pp.335-9. https://pubmed.ncbi.nlm.nih.gov/8161083/
Torres JR, Liprandi F, Goncalvez AP. Atypical parotitis due to dengue virus. Clin Infect Dis.2000; 31(5):pp.28-29. https://pubmed.ncbi.nlm.nih.gov/11073786/
Gonzalez GR, Henao AF. Dengue hemorrhagic fever complicated by pancreatitis. Braz J Infect Dis.2011; 15(5):pp.490–92. https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000500015
Setiawan MW, Samsi TK, Wulur H, Sugianto D, Pool TN. Epigastric pain and sonographic assessment of the pancreas in dengue. J Clin Ultrasound.1997; 26(5):pp.257–9. https://pubmed.ncbi.nlm.nih.gov/9608369/
Gupta VK, Lalchandani A, Agrawal K. Neurological manifestations of dengue infection. Ann Trop Med Public Health.2015; 8:pp.117-21. http://www.atmph.org/text.asp?2015/8/4/117/162370
Chen WJ, Huang KP, Fang AH. Detection of IgM antibodies from cerebrospinal fluid and sera of dengue fever patients. Southeast Asian J Trop Med Public Health.1991; 22:pp.659-63. https://pubmed.ncbi.nlm.nih.gov/1820657/
Lum LC, Lam SK, Choy YS, George R, Harun F. Dengue encephalitis: A true entity? Am J Top Med Hyg.1996; 54:pp.256-9. https://pubmed.ncbi.nlm.nih.gov/8600761/
Jackson ST, Mullings A, Bennett F, Khan C, Gordon-Strachan G,
et l. Dengue infection in patients presenting with neurological manifestations in a dengue-endemic population. West Indian Med J.2008; 57:pp.373-6. https://pubmed.ncbi.nlm.nih.gov/19566019/
Kunishige M, Mitsui T, Tan BH, Leong HN, Takasaki T, et al. Preferential gray matter involvement in dengue myelitis. Neurology.2004; 63:pp.1980-1. https://pubmed.ncbi.nlm.nih.gov/15557535/
Soares CN, Cabral-Castro MJ, Peralta JM, Freitas MR, Puccioni-Sohler M. Meningitis determined by oligosymptomatic dengue virus type 3 infection: Report of a case. Int J Infect Dis.2010; 14:e150-2. https://pubmed.ncbi.nlm.nih.gov/19501535/
Mathew S, Pandian JD. Stroke in patients with dengue. J Stroke Cerebrovasc Dis.2010; 19:pp.253-6. https://pubmed.ncbi.nlm.nih.gov/20434057/
Tomar LR, Raizada A, Yadav A, Agarwal S. Dengue fever presenting as hypokalaemic muscle weakness. Trop J Med Res.2016; 19:pp.76-8. http://www.tjmrjournal.org/text.asp?2016/19/1/76/172058
Trung DT, Wills B. Systemic vascular leakage associated with dengue infection - the clinical perspective. Curr Top Microbiol Immunol.2010; 338:pp.57-66. https://pubmed.ncbi.nlm.nih.gov/19802578/
Mairuhu AT, Setiati TE, Koraka P, Hack CE, Leyte A, Faradz SM, et al. Increased PAI-I plasma levels and risk of death from dengue: No association with the 4G/5G promoter polymorphism. Thromb J.2005; 3:pp.17-25. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1308869/
Brito CA, Sobreira S, Cordeiro MT, Lucena-Silva N. Acute disseminated encephalomyelitis in classic dengue. Rev Soc Bras Med Trop.2007; 40:pp.236-8. https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822007000200019
Seet RC, Lim EC, Wilder-Smith EP. Acute transverse myelitis following dengue virus infection. J Clin Virol.2006; 35:pp.310-2.
de Aragao RE, Barreira IM, Lima LN, Rabelo LP, Pereira FB. Bilateral optic neuritis after dengue viral infection: Case report. Arq Bras Oftalmol.2010; 73:pp.175-8. https://pubmed.ncbi.nlm.nih.gov/20549049/
Ansari MK, Jha S, Nath A. Unilateral diaphragmatic paralysis following dengue infection. Neurol India.2010; 58:pp.596-8.
Donnio A, Beral L, Olindo S, Cabie A, Merle H. Dengue, a new etiology in oculomotor paralysis. Can J Ophthalmol.2010; 45:pp.183-4.
Bacsal KE, Chee SP, Cheng CL, Flores JV. Dengue-associated maculopathy. Arch Ophthalmol.2007; 125:pp.501-10. https://pubmed.ncbi.nlm.nih.gov/17420370/
Seet RC, Quek AM, Lim EC. Post-infectious fatigue syndrome in dengue infections. J Clin Virol.2007; 38:pp.2-6.
Datta G, Mitra P. A Study on Cardiac Manifestations of Dengue Fever. J Assoc Physicians India.2019; 67:pp.14-16. https://pubmed.ncbi.nlm.nih.gov/31559761/
Wiwanikit. Dengue Cardiac Infection, A Brief Review. Acta Cardiol Sin.2008; 24:226. https://www.ijmedicine.com/index.php/ijam/article/view/535
Kaushik JS, Gupta P, Rajpal S, Bhatt S. Spontaneous resolution of sinoatrial exit block and atrioventricular dissociation in a child with dengue fever. Singapore Med J.2010; 51(9):e146-8. https://pubmed.ncbi.nlm.nih.gov/20938598/
Lum LC, Thong MK, Cheah YK, Lam SK. Dengue-associated adult respiratory distress syndrome. Ann Trop Paediatr.1995; 15(4):pp.335-9. https://pubmed.ncbi.nlm.nih.gov/8687212/
Miyata N, Yoshimura Y, Tachikawa N, Amano Y, Sakamoto Y,et al. Cavity Forming Pneumonia Due to Staphylococcus aureus Following Dengue Fever. Am J Trop Med Hyg.2015; 93(5):pp.1055-7. https://pubmed.ncbi.nlm.nih.gov/26304914/
Macedo RN, Rocha FA, Rolim DB, Vilar DC, Araújo FM, et al. Severe coinfection of melioidosis and dengue fever in Northeastern Brazil: first case report. Rev Soc Bras Med Trop.2012; 45(1):pp.132-3. https://doi.org/10.1590/S0037-86822012000100028
Wiwanitkit V. Lund Disease in Dengue. Journal of Resp Research.2015; 1(1):pp.7-9. http://www.ghrnet.org/index.php/jrr/article/view/1372/1791
Vachvanichsanong P, Thisyakorn U, Thisyakorn C. Dengue hemorrhagic fever and the kidney. Arch Virol.2016; 161(4):pp.771-8. https://pubmed.ncbi.nlm.nih.gov/26699788/
Eswarappa M, Reddy SB, John MM, Suryavara S, Madhyashatha RP. Renal manifestations of dengue viral infection. Saudi J Kidney Dis Transpl.2019; 30:pp.394-400. http://www.sjkdt.org/text.asp?2019/30/2/394/256847
Ramachandran B, Balasubramanian S, Abhishek N, Ravikumar KG, Ramanan AV. Profile of hemophagocytic lymphohistiocytosis in children in a tertiary care hospital in India. Indian Pediatr.2011; 48:pp.31–5. https://pubmed.ncbi.nlm.nih.gov/20972297/
Ray S, Kundu S, Saha M, Chakrabarti P. Hemophagocytic Syndrome in Classic Dengue Fever. J Glob Infect Dis.2011;3(4):pp.399–401. http://www.jgid.org/text.asp?2011/3/4/399/91068
Karras A, Hermine O. Macrophage activation syndrome. Rev Med Interne.2002; 23:pp.768–78. http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=235&doi=10.11648/j.ajlm.20200501.14
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer.2007; 48(2):pp.124-31. https://pubmed.ncbi.nlm.nih.gov/16937360/
de Azeredo EL, Monteiro RQ, de-Oliveira Pinto LM. Thrombocytopenia in Dengue: Interrelationship between Virus and the Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators. Mediators Inflamm.2015; 2015: 313842. https://pubmed.ncbi.nlm.nih.gov/25999666/
Huang YH, Liu CC, Wang ST, Lei HY, Liu HL, et al. Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol.2001; 63(3):pp.247-51. https://pubmed.ncbi.nlm.nih.gov/11170065/
Rao IS, Loya AC, Ratnakar KS, Srinivasan VR. Lymph node infarction -a rare complication associated with disseminated intravascular coagulation in a case of dengue fever. BMC Clin Pathol.2005;5:11. https://bmcclinpathol.biomedcentral.com/articles/10.1186/1472-6890-5-11
Karakus A, Banga N, Voorn GP, Meinders AJ. Dengue shock syndrome and rhabdomyolysis. Neth J Med.2007; 65:pp.78-81. https://pubmed.ncbi.nlm.nih.gov/17379934/
Downloads
Additional Files
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
